Microbot Medical Secures First International Approval for LIBERTY Robotic System in Israel
Event summary
- Microbot Medical received marketing clearance for its LIBERTY Endovascular Robotic System in Israel, its first international approval outside the U.S.
- The AMAR approval enables the company to obtain a Free Sale Certificate for submissions in additional jurisdictions.
- Microbot continues to pursue CE Mark certification, targeting completion by the end of 2026 for EU market expansion.
- The LIBERTY System is already adopted in multiple U.S. hospitals across Georgia, Florida, New York, Massachusetts, Michigan, and North Carolina.
The big picture
Microbot Medical's regulatory approval in Israel marks a strategic step in its international expansion, following its successful U.S. launch. The approval supports the company's efforts to secure a Free Sale Certificate, which is essential for entering additional markets. The broader trend of robotic-assisted medical procedures is gaining traction, and Microbot's ability to navigate regulatory pathways will be key to its competitive positioning in the endovascular technology space.
What we're watching
- Regulatory Momentum
- The pace at which Microbot secures additional international approvals will determine its global market penetration.
- Commercial Execution
- Whether Microbot can leverage the Israeli approval to accelerate adoption in other non-U.S. markets.
- EU Market Entry
- The timeline and success of obtaining CE Mark certification will be critical for expanding into the European market.
Related topics